Bonesupport: CERAMENT, Bone Infections & Use Cases
Former Sales Manager at Bonesupport
inpractise.com/articles/bonesupport-cerament-bone-infections-and-use-cases
Bonesupport: CERAMENT, Bone Infections & Use Cases(August 21, 2024)
Former Sales Manager at Bonesupport
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Why is the addition of the second material so important?
The results from studies and clinical reports show that calcium sulfate is reabsorbed by the body quite quickly. The inventors of CERAMENT believed that to aid bone cell growth, the addition of hydroxyapatite would be beneficial. Hydroxyapatite acts as a scaffold inside the body, providing a structure for the growing bone cells to use, leading to more solid and complete bone regeneration.
This is a snippet of the transcript, sign up to read more.
Yes, that makes sense. If we think about the type of physician that uses CERAMENT, is it just orthopedic surgeons? Who are the key users of CERAMENT?
However, literature indicates that only 10% of the total antibiotic administered reached the bone infection, making it very ineffective. This meant that after four to six months, patients often returned with recurring bone infections. Even a small piece of infected bone left untreated could lead to bacterial colonization and reinfection. It was a nightmare for surgeons to deal with patients with bone infections, which often worsened over time, sometimes leading to amputations. It was a very complex problem with very complex patients.
This is a snippet of the transcript, sign up to read more.
Related Content
Bonesupport: US Sales Process & Growth Opportunity
Former Sales Executive at Bonesupport
Bonesupport: History, Competition & Market Size
Former Senior Sales Executive at Bonesupport
Becton Dickinson: M&A History, Culture & Management
Former Senior Executive at Becton Dickinson
Becton Dickinson: Leadership Style & Organic Growth
Former Senior Executive at Becton Dickinson
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.